Form 4: Liquidia Director Stephen Bloch Granted 18,396 Restricted Stock Units

Liquidia Corp. Director Stephen M. Bloch was granted 18,396 Restricted Stock Units (RSUs) on June 17, 2025, as part of his compensation, which will convert to common stock upon vesting.

Summary

• Stephen M. Bloch, a Director of Liquidia Corp. (LQDA), acquired 18,396 Restricted Stock Units (RSUs).
• The transaction occurred on June 17, 2025.
• These RSUs convert into common stock on a one-for-one basis.
• The RSUs were granted at a price of $0, indicating they are compensation.
• Following this transaction, Mr. Bloch beneficially owns 38,755 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged plan for the acquisition of equity securities.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a routine compensation event, generally viewed as neutral to slightly positive as it aligns director interests with shareholders. It does not indicate significant operational or financial news.

Positives

• The grant of RSUs to a director aligns their interests with shareholders, incentivizing long-term company performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation structure.

Future Outlook

The 18,396 Restricted Stock Units granted to Director Stephen M. Bloch are scheduled to vest upon the earlier of the one-year anniversary of the grant date (June 17, 2026) or the day prior to Liquidia Corp.'s next annual shareholder meeting following the grant date.

Industry Context

This RSU grant is a standard form of equity compensation for directors in the biotechnology or pharmaceutical industry, aiming to align executive interests with long-term shareholder value. Such grants are a common practice to attract and retain experienced board members.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common practice in publicly traded companies, particularly within the life sciences sector, as a component of non-cash compensation.
• While specific comparable companies or projects are not detailed in this filing, RSU grants are widely used by peers like United Therapeutics Corporation (UTHR) or other mid-cap biotech firms to incentivize long-term commitment and performance.
• The vesting schedule, tied to either a one-year anniversary or the next annual shareholder meeting, is also a typical structure for director equity awards, ensuring continued engagement and alignment with corporate milestones.

Related Party Transactions

• The grant of 18,396 Restricted Stock Units to Stephen M. Bloch, a Director of Liquidia Corp., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders through equity ownership, potentially fostering long-term value creation. It represents a non-cash compensation expense for the company.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Vesting of the 18,396 Restricted Stock Units upon the earlier of June 17, 2026, or the day prior to the next annual shareholder meeting.
• Conversion of vested RSUs into common stock.

Key Dates

Keywords

Liquidia Corp, LQDA, Stephen M. Bloch, Form 4, SEC Filing, Restricted Stock Units, RSUs, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership